KW-2449
- Generic Name
- KW-2449
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT00779480
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸St. Francis Hospital, Greenville, South Carolina, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1
Terminated
- Conditions
- Acute Lymphoblastic LeukemiaMyelodysplastic SyndromesAcute Myelogenous LeukemiaChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00346632
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Contact Kyowa, Princeton, New Jersey, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath